These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11807660)

  • 1. [Are COX-2 inhibitors a risk factor for cardiovascular disease?].
    John S; Schmieder RE
    Dtsch Med Wochenschr; 2002 Jan; 127(4):156-9. PubMed ID: 11807660
    [No Abstract]   [Full Text] [Related]  

  • 2. [Coxib debate on thin ice].
    Järhult B
    Lakartidningen; 2005 Mar 7-13; 102(10):788-9; discussion 789-90. PubMed ID: 15839175
    [No Abstract]   [Full Text] [Related]  

  • 3. [COX 2 inhibitors--a further step back].
    Slørdal L; Evensen S; Spigset O
    Tidsskr Nor Laegeforen; 2005 Apr; 125(8):1046. PubMed ID: 15852094
    [No Abstract]   [Full Text] [Related]  

  • 4. The practice implications of cardiovascular risks in NSAIDs.
    Hainsworth T
    Nurs Times; 2005 Jun 28-Jul 4; 101(26):26-7. PubMed ID: 16010838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Undesired effects of NSAIDS and coxibs].
    Fauler J
    MMW Fortschr Med; 2005 Aug; 147(31-32):31-5. PubMed ID: 16128194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2 inhibitors. Understanding recent concerns.
    Mayo Clin Health Lett; 2002 Oct; 20(10):6. PubMed ID: 12425271
    [No Abstract]   [Full Text] [Related]  

  • 7. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
    Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
    [No Abstract]   [Full Text] [Related]  

  • 8. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease?
    Messerli FH; Sichrovsky T
    Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380
    [No Abstract]   [Full Text] [Related]  

  • 9. Life without COX 2 inhibitors: risks and benefits are determined by dose and potency.
    Sánchez-Delgado EJ
    BMJ; 2006 Jun; 332(7555):1451-2. PubMed ID: 16777893
    [No Abstract]   [Full Text] [Related]  

  • 10. Does celecoxib use increase the risk of cardiovascular events?
    Oviedo JA; Schroy PC
    Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal.
    Baigent C; Patrono C
    Arthritis Rheum; 2003 Jan; 48(1):12-20. PubMed ID: 12528099
    [No Abstract]   [Full Text] [Related]  

  • 12. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Bijlsma JW
    Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Smith ER
    Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
    [No Abstract]   [Full Text] [Related]  

  • 14. Rescuing COX-2 inhibitors from the waste bin.
    Albini A; Noonan DM
    J Natl Cancer Inst; 2005 Jun; 97(11):859-60. PubMed ID: 15928309
    [No Abstract]   [Full Text] [Related]  

  • 15. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 17. [A step back or training pain?].
    Raeder J
    Tidsskr Nor Laegeforen; 2005 Aug; 125(15):2050-1. PubMed ID: 16100553
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Slime fight in the lay media. Were the Vioxx fatal cases kept secret?].
    Zierenberg O
    MMW Fortschr Med; 2004 Oct; 146(43):60. PubMed ID: 15559526
    [No Abstract]   [Full Text] [Related]  

  • 20. Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
    Giannitsis E
    Clin Lab; 2005; 51(1-2):63-83. PubMed ID: 15719708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.